GRAIL, Inc. — Form 8-K
Filed August 5, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 52/100
What the filing says
GRAIL reported Q2 2026 total revenue of $44.7M (up 26% YoY) with Galleri screening revenue of $42.6M (up 24% YoY) and 61,000+ tests (up 35% YoY). The company completed a $110M equity financing with Samsung C&T Corporation and Samsung Electronics for commercialization rights in South Korea and potential Asian expansion. Net loss was $110.2M; adjusted EBITDA was $(90.3)M. FDA advisory committee anticipated fall 2026. Cash position: $861.6M.
Why this rating
Samsung $110M financing (~5.8% of market cap) validates product and funds operations; strong revenue growth (+26%) and test volume growth (+35%) show commercial traction. However, company still unprofitable on GAAP basis with large net loss; regulatory approval (FDA PMA) remains uncertain. Material but not transformational at this scale.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.